Thomas Quinn is a Rheumatology/Immunology physician. ClinicalTrials.gov lists 10 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
583 Skippack Pike Ste 600
Blue Bell, PA 194222168
Telephone
215-872-5650Provider last certified this registry record 25 Aug 2025.
Clinical trials
- APIOC for Presbyopia and APIOC for Presbyopia With Astigmatism
Sponsor: Lentechs, LLC
- Apioc Toric/Spherical Single Vision Contact Lens
Sponsor: Lentechs, LLC
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
28 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year202547 payments
- AstraZeneca Pharmaceuticals LPProgram year202531 payments
- ABBVIE INC.Program year202523 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
31.9%Beta blocker6.9%Metoprolol Succinate46%Metoprolol Tartrate27%Carvedilol11%Atenolol8%Propranolol Hcl5%Timolol Maleate2%Nebivolol Hcl2%Part D<11 patientsStatin6.2%Atorvastatin Calcium63%Simvastatin19%Rosuvastatin Calcium10%Pravastatin Sodium8%Part D<11 patients+ 12 more classes in this area
Nervous system
19.4%SSRI5.1%Escitalopram Oxalate41%Sertraline Hcl29%Trazodone Hcl20%Citalopram Hbr8%Paroxetine Hcl3%Part D<11 patientsOther antidepressants2.5%Mirtazapine100%Part D≥47 patients+ 15 more classes in this area
Metabolism & gastrointestinal
14.1%Proton pump inhibitor4.7%Pantoprazole Sodium66%Omeprazole32%Dexlansoprazole Dr3%Part D<11 patientsPotassium supplement3%Potassium Chloride100%Part D≥53 patients+ 12 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”